Synthetic TLR4 agonist as a potential immunotherapy for melioidosis

Zi Yan Tan, Alvin K. L. Khah, Siew Hoon Sim, Vidhya Novem, Yichun Liu, Gek-Yen Gladys Tan

Host-Pathogen Interaction Laboratory, Defence Medical & Environmental Research Institute, DSO National Laboratories, Singapore City, Singapore.

DOI: 10.4236/oji.2013.31001                

Abstract

Melioidosis, an infection caused by Gram-negative Burkholderia pseudomallei (Bp), has high clinical recurrence and mortality rates associated with pneumonia and sepsis. With the limitations in current therapeutic options and the lack of available human vaccines, development of novel countermeasures against Bp infection is vital. In this study, we evaluated the efficacy of an aminoalkyl glucosaminide 4-phosphate (AGP), a synthetic toll like receptor 4 agonist (CRX-527), in conferring protection against melioidosis in a murine model. Survival data showed 66% of mice treated with AGP prior to lethal intranasal Bp challenge survived and presented no signs of illness over a 3 months period. In contrast, all control mice succumbed to infection within 4 days. Kinetic study on organ bacterial burden demonstrated mice treated with AGP had dramatically reduced bacterial loads in both the lungs and spleens as compared to control mice. Notably, all but one AGP-treated mouse had no Bp growth in the blood as compared to overwhelming bacteraemia found in all control mice. The protective effect of CRX-527 was associated with a transient increase in pulmonary cytokine/ chemokine levels, which boosted the host’s innate immunity. This enabled rapid clearance of the pulmonary and systemic bacterial burden and prevented the development of sepsis. This study demonstrated the potential use of TLR4 agonist as a prophylactic immunotherapy in preventing melioidosis.

Keywords

Melioidosis; AGP; Pneumonia; Sepsis; TLR4 Agonist; Bukholderia pseudomallei

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Lazar Adler, N.R., Govan, B., Cullinane, M., et al. (2009) The molecular and cellular basis of pathogenesis in melioidosis: How does Burkholderia pseudomallei cause disease? FEMS Microbiology Reviews, 33, 1079-1099. doi:10.1111/j.1574-6976.2009.00189.x
[2]	Inglis, T.J., Rolim, D.B. and Sousa Ade, Q. (2006) Melioidosis in the Americas. The American Journal of Tropical Medicine and Hygiene, 75, 947-954. Cuadros, J., Gil, H., Miguel, J. D., et al. (2011) Case report: Melioidosis imported from West Africa to Europe. The American Journal of Tropical Medicine and Hygiene, 85, 282-284. doi:10.4269/ajtmh.2011.11-0207
[3]	Gan, Y.-H. (2005) Interaction between Burkholderia pseudomallei and the host immune response: Sleeping with the enemy? Journal of Infectious Diseases, 192, 1845-1850. doi:10.1086/497382
[4]	Gan, Y.-H. (2005) Interaction between Burkholderia pseudomallei and the host immune response: Sleeping with the enemy? Journal of Infectious Diseases, 192, 1845-1850. doi:10.1086/497382
[5]	Limmathurotsakul, D. and Peacock, S.J. (2011) Melioidosis: A clinical overview. British Medical Bulletin, 99, 125-139. doi:10.1093/bmb/ldr007
[6]	White, N.J. (2003) Melioidosis. Lancet, 361, 1715-1722. doi:10.1016/S0140-6736(03)13374-0
[7]	Patel, N., Conejero, L., De Reynal, M., Easton, A., Bancroft, G.J. and Titball, R.W. (2011) Development of vaccines against Burkholderia pseudomallei. Frontiers in Microbiology, 2, 198. doi:10.3389/fmicb.2011.00198
[8]	Cheng, A.C. and Currie, B.J. (2005) Melioidosis: Epidemiology, pathophysiology, and management. Clinical Microbiology Reviews, 18, 383-416. doi:10.1128/CMR.18.2.383-416.2005
[9]	Wiersinga, W.J., van der Poll, T., White, N.J., Day, N.P. and Peacock, S.J. (2006) Melioidosis: Insights into the pathogenicity of Burkholderia pseudomallei. Nature Reviews Microbiology, 4, 272-282. doi:10.1038/nrmicro1385
[10]	Propst, K.L., Troyer, R.M., Kellihan, L.M., Schweizer, H.P. and Dow, S.W. (2010) Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrobial Agents and Chemotherapy, 54, 1785-1792. doi:10.1128/AAC.01513-09
[11]	Powell, K., Ulett, G., Hirst, R. and Norton, R. (2003) G-CSF immunotherapy for treatment of acute disseminated murinemelioidosis. FEMS Microbiology Letters, 224, 315-318. doi:10.1016/S0378-1097(03)00473-7
[12]	Cheng, A.C., Limmathurotsakul, D., Chierakul, W., Getchalarat, N., Wuthiekanun, V., Stephens, D.P., Day, N.P., White, N.J., Chaowagul, W., Currie, B.J. and Peacock, S.J. (2007) A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clinical Infectious Diseases, 45, 308-314. doi:10.1086/519261
[13]	Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: Update on tolllike receptors. Nature Immunology, 11, 373-384. doi:10.1038/ni.1863
[14]	Novem, V., Shui, G., Wang, D., et al. (2009) Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clinical and Vaccine Immunology, 16, 1420-1428. doi:10.1128/CVI.00472-08
[15]	Rowe, D.C., McGettrick, A.F., Latz, E., et al. (2006) Themyristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proceedings of the National Academy of Sciences, 103, 6299-6304. doi:10.1073/pnas.0510041103
[16]	Gibbons, H.S., Lin, S., Cotter, R.J. and Raetz, C.R. (2000) Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A. Function of LpxO, a new Fe2+/alpha-ketoglutarate-depen dent dioxygenase homologue. The Journal of Biological Chemistry, 275, 32940-32949. doi:10.1074/jbc.M005779200
[17]	Johnson, A.G. (1994) Molecular adjuvants and immunomodulators: New approaches to immunization. Clinical Microbiology Reviews, 7, 277-289.
[18]	Airhart, C.L., Rohde, H.N., Bohach, G.A., et al. (2008) Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology, 154, 2131-2138. doi:10.1099/mic.0.2008/017566-0
[19]	Baldridge, J.R., Cluff, C.W., Evans, J.T., et al. (2002) Immunostimulatory activity of aminoalkylglucosaminide 4-phosphates (AGPs): Induction of protective innate immune responses by RC-524 and RC-529. Journal of Endotoxin Research, 8, 453-458.
[20]	Lembo, A., Pelletier, M., Iyer, R., et al. (2008) Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. The Journal of Immunology, 180, 7574-7581.
[21]	Bowen, W.S., Minns, L.A., Johnson, D.A., et al. (2012) Selective TRIF-dependent signaling by a synthetic tolllike receptor 4 agonist. Science Signaling, 5, ra13. doi:10.1126/scisignal.2001963
[22]	Cluff, C.W., Baldridge, J.R., Stover, A.G., et al. (2005) Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infection and Immunity, 73, 3044-3052. doi:10.1128/IAI.73.5.3044-3052.2005
[23]	Stover, A.G., Da Silva Correia, J., Evans, J.T., et al. (20 04) Structure-activity relationship of synthetic toll-like receptor 4 agonists. The Journal of Biological Chemistry, 279, 4440-4449. doi:10.1074/jbc.M310760200
[24]	Currie, B.J. (2003) Melioidosis: An important cause of pneumonia in residents of and travellers returned from endemic regions. European Respiratory Journal, 22, 542-550. doi:10.1183/09031936.03.00006203
[25]	Sim, S.H., Liu, Y., Wang, D., et al. (2009) Innate immune responses of pulmonary epithelial cells to Burkholderia pseudomallei infection. PLoS One, 4, Article ID: e7308. doi:10.1371/journal.pone.0007308
[26]	Johnson, D.A. (2008) Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Current Topics in Medicinal Chemistry, 8, 64-79. doi:10.2174/156802608783378882
[27]	Guthrie, L.A., McPhail, L.C., Henson, P.M. and Johnston Jr., R.B., (1984) Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. The Journal of Experimental Medicine, 160, 1656-1671. doi:10.1084/jem.160.6.1656
[28]	Sheppard, F.R., Kelher, M.R., Moore, E.E., et al. (2005) Structural organization of the neutrophil NADPH oxidase: Phosphorylation and translocation during priming and activation. Journal of Leukocyte Biology, 78, 1025-1042. doi:10.1189/jlb.0804442
[29]	Wiersinga, W.J., Wieland, C.W., Roelofs, J.J. and van der Poll, T. (2008) MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei. PLoS One, 3, Article ID: e3494. doi:10.1371/journal.pone.0003494
[30]	Vincent, J.L. (2008) Clinical sepsis and septic shock-definition, diagnosis and management principles. Langenbeck’s Archives of Surgery, 393, 817-824. doi:10.1007/s00423-008-0343-1
[31]	Blackwell, T.S. and Christman, J.W. (1996) Sepsis and cytokines: Current status. British Journal of Anaesthesia, 77, 110-117. doi:10.1093/bja/77.1.110
[32]	Ramnath, R.D., Ng, S.W., Guglielmotti, A. and Bhatia, M. (2008) Role of MCP-1 in endotoxemia and sepsis. International Immunopharmacology, 8, 810-818. doi:10.1016/j.intimp.2008.01.033
[33]	Lauw, F.N., Simpson, A.J., Prins, J.M., et al. (1999) Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)18, IL-12, and IL-15 in severe melioidosis. Journal of Infectious Diseases, 180, 1878-1885. doi:10.1086/315155
[34]	Wiersinga, W.J., Wieland, C.W., van derWindt, G.J., et al. (2007) Endogenous interleukin-18 improves the early antimicrobial host response in severe melioidosis. Infection and Immunity, 75, 3739-3746. doi:10.1128/IAI.00080-07
[35]	Brown, A.E., Dance, D.A., Suputtamongkol, Y., et al. (1991) Immune cell activation in melioidosis: Increased serum levels of interferon-gamma and soluble interleukin2 receptors without change in soluble CD8 protein. Journal of Infectious Diseases, 163, 1145-1148. doi:10.1093/infdis/163.5.1145
[36]	Ulett, G.C., Ketheesan, N. and Hirst, R.G. (2000) Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infection and Immunity, 68, 2034-2042. doi:10.1128/IAI.68.4.2034-2042.2000
[37]	Barnes, J.L., Ulett, G.C., Ketheesan, N., et al. (2001) Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection. Immunology and Cell Biology, 79, 490-501. doi:10.1046/j.1440-1711.2001.01038.x
[38]	Liu, B., Koo, G.C., Yap, E.H., Chua, K.L. and Gan, Y.H. (2002) Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infection and Immunity, 70, 504-511. doi:10.1128/IAI.70.2.504-511.2002
[39]	Tan, G.Y., Liu, Y., Sivalingam, S.P., et al. (2008) Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. Journal of Medical Microbiology, 57, 508-515. doi:10.1099/jmm.0.47596-0
[40]	Lertmemongkolchai, G., Cai, G., Hunter, C.A. and Bancroft, G.J. (2001) Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. The Journal of Immunology, 166, 1097-1105.
[41]	Santanirand, P., Harley, V.S., Dance, D.A., Drasar, B.S. and Bancroft, G.J. (1999) Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infection and Immunity, 67, 3593-3600.
[42]	Wheeler, D.S., Lahni, P.M., Denenberg, A.G., et al. (2008) Induction of endotoxin tolerance enhances bacterial clearance and survival in murinepolymicrobial sepsis. Shock, 30, 267-273.